ON1231320 is a potent selective inhibitor of Polo like kinase 2 (PLK2).

Abiraterone acetate is an FDA approved drug, and is an orally active acetate ester of the steroidal compound abiraterone with antiandrogen activity. Abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA) in April 2011. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. FDA Approval this drug in May 2011.

SBI-477 is a chemical probe that coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes with EC50 of 100 nM and 1 uM, respectively.

AZ10606120 is a potent, specific P2X7 receptor antagonist with Kd of 1.4 and 19 nM at human and rat P2X7 receptors respectively.

GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations.

Polymyxin B is an antibiotic primarily used for resistant gram-negative infections.

BDP-13176 is a potent fascin 1 inhibitor, with a Kd of 90 nM and an IC50 of 240 nM. BDP-13176 has potential as an anti-metastatic agent.

DM-PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain, PIP3/PDK1 PH domain, and PIP3/GRP1 PH domain with IC50 of 27.1 uM, 80.5 uM, and 35.5 uM, respectively.

Thr-Asp-F-amidine (TDFA) is a highly potent, selective PAD4 (protein arginine deiminase 4) inhibitor with IC50 of 2.3 uM, displays ≥15-fold selectivity for PAD4 versus PAD1 and ≥50-fold versus PADs 2 and 3.

Apomorphine hydrochloride hemihydrate is a non-selective dopamine agonist which activates both D1-likeand D2-like receptors, with some preference for the latter subtypes..

Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

Novel HCN4 CLP ligand, modulating channel function and completely abolishing the cAMP-induced shift in V1/2

Novel selective inhibitor of collagen prolyl 4-hydroxylase, neither causing general toxicity nor disrupting iron homeostasis

Novel glucocerebrosidase activator; Non-inhibitory chaperones of glucocerebrosidase

BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor..

Novel modulator of the UNC119-Cargo Interaction, potently and selectively inhibiting the binding of a myristoylated peptide representing the N-terminus of Src kinase to UNC119A

A potent and efficacious hERG channel activator steeply potentiates current amplitudes more than 10-fold with EC50 of 0.5 uM.

Potent and selective blocker for TMEM16A/Anoctamin-1 (ANO1)

TM5007 is a poent inhibitor plasminogen activator inhibitor-1 (PAI-1) with IC50 of 29 uM, exhibits no inhibitory activity against any of the closely related serpins or serine proteases at 250 uM. .

Novel blood brain barrier (BBB) penetrable two-photon imaging probe, labelling plaques and cerebral amyloid angiopathies (CAAs)

Potent and selective mGluR8-specific orthosteric agonist

Novel selective PAD4 inhibitor

Potent and ATP-binding site inhibitor of GSK-3

Novel potent and selective RIP3 kinase inhibitor

A non-peptide small molecule agonist of the PTH1 receptor, activates both the cAMP and calcium signaling pathways..

Novel potent agonist of HTL/KAI2, stimulating activity for Arabidopsis seed germination

DPI-201-106 is a cardioselective inhibitor of the TTX-resistant h1 Na channel inactivation. DPI-201-106 inhibits the L-type calcium current, and inward and delayed rectifier potassium currents.

Potent, orally active and S1P3-sparing S1P1 agonist

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models

Novel VISTA (V-domain immunoglobulin suppressor of T-cell activation) agonist